Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 May 29;5(7):100693.
doi: 10.1016/j.jtocrr.2024.100693. eCollection 2024 Jul.

Trophoblast Cell Surface Antigen 2 Expression in Thymic Carcinoma: Brief Report

Kana Kurokawa  1 , Tetsuhiko Asao  1 , Takuo Hayashi  2 , Satsuki Kishikawa  2 , Koichiro Kanamori  1 , Takehito Shukuya  1 , Yosuke Miyashita  1 , Ikuko Nakamura  1 , Taichi Miyawaki  1 , Ryota Kanemaru  1 , Tomoyasu Mimori  1 , Yoichiro Mitsuishi  1 , Ken Tajima  1 , Naoko Shimada  1 , Fumiyuki Takahashi  1 , Kazuya Takamochi  3 , Kenji Suzuki  3 , Kazuhisa Takahashi  1
Affiliations

Trophoblast Cell Surface Antigen 2 Expression in Thymic Carcinoma: Brief Report

Kana Kurokawa et al. JTO Clin Res Rep. .

Abstract

Introduction: Trophoblast cell surface antigen 2 (TROP2) is a transmembrane glycoprotein overexpressed in various cancer types. Although TROP2-targeting therapy is currently attracting attention, little is known about TROP2 expression in thymic carcinoma.

Methods: TROP2 gene expression in thymic epithelial tumors was analyzed using RNA-sequencing (RNA-seq) data for 122 cases obtained from The Cancer Genome Atlas. Immunohistochemistry (IHC) staining with anti-TROP2 antibody (SP295) was performed in 26 cases of thymic carcinoma tissues surgically resected at Juntendo University.

Results: RNA-seq data analysis from The Cancer Genome Atlas revealed that TACSTD2 (gene encoding TROP2) expression was significantly higher in thymic carcinoma than in thymoma (adjusted p = 6.64e-05). There was also a trend of increasing expression in the order of thymoma type B1, B2, B3, and thymic carcinoma. As for IHC in thymic carcinoma, TROP2 expression was localized to the membrane of cancer cells. Intensity 0, 1, and 2 was observed in six (23.1%), 11 (42.3%), and nine (34.6%) cases, respectively, leading to TROP2 positivity in 20 cases (76.9%). The median proportion of TROP2-positive tumor cells and the median H-score were 25.0% (range: 0%-100%) and 25.0 (range: 0-200), respectively. No relevant factors were identified in the analysis of TROP2 expression and patient background. Although not significant, high TROP2 expression (H-score ≥ 50) tended to be associated with shorter survival.

Conclusions: TROP2 expression in thymic carcinoma was confirmed by both RNA-seq and IHC, with high expression observed in IHC for intensity (76.9%) and proportion. TROP2 could be a potential target in thymic carcinoma.

Keywords: Immunohistochemistry; RNA-seq; TROP2; Thymic carcinoma.

PubMed Disclaimer

Conflict of interest statement

Dr. Asao reports honoraria from AstraZeneca K.K., Bristol-Myers K.K., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Eli Lilly Japan K.K, Merck Biopharma Co., Ltd., Merck Sharp & Dohme K.K, Nippon Boehringer Ingelheim Co., Ltd., Nippon Kayaku Co., Ltd., Ono Pharmaceutical Co., Ltd., Pfizer Inc., Taiho Pharmaceutical Co., Ltd., and Takeda Pharmaceutical Company Limited outside of the submitted work. Dr. Shukuya reports grants and honoraria from AstraZeneca K.K., Chugai Pharmaceutical Co., Ltd., Nippon Boehringer Ingelheim Co., Ltd., Novartis Pharma K.K., and Merck Sharp & Dohme K.K. and honoraria from Taiho Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Ono Pharmaceutical Co., Ltd., Bristol-Myers Squibb Company, Nippon Kayaku Co., Ltd., Takeda Pharmaceutical Company, Pfizer Inc., and Eisai Co., Ltd. outside of the submitted work. Dr. Fumiyuki Takahashi reports grants from 10.13039/100004325AstraZeneca, 10.13039/100017346Nippon Boehringer Ingelheim, 10.13039/100009947Merck Sharp & Dohme, 10.13039/100004336Novartis, and Lilly Japan outside of the submitted work. Dr. Kazuhisa Takahashi reports grants and honoraria from Chugai Pharmaceutical Co., Ltd., Nippon Boehringer Ingelheim Co., Ltd., Pfizer Inc., Taiho Pharmaceutical Co., Ltd., Kyorin Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., Novartis Pharma K.K., Eli Lilly Japan K.K., Nippon Kayaku Co., Ltd., Takeda Pharmaceutical Company Limited, and grants from 10.13039/100018036Nippon Shinyaku Co., Ltd., Tsumura & Co., Teijin Pharma Limited, 10.13039/100015990Sanofi K.K., Shionogi & Co., Ltd., Bayer Yakuhin, Ltd., 10.13039/501100002973Daiichi Sankyo Co., Ltd., Nipro Pharma Corporation, 10.13039/100010740Asahi Kasei Pharma Corporation, Kyowa Kirin Co., Ltd., and honoraria from Merck Sharp & Dohme K.K., AstraZeneca K.K., Merck Biopharma Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Bristol-Myers K.K., Meiji Seika Pharma Co., Ltd., Viatris Inc., Janssen Pharmaceutical K.K., Abbott Japan LLC, and Thermo Fisher Scientific Inc. outside the submitted work. The remaining authors declare no conflict of interest.

Figures

Figure 1
Figure 1
TACSTD2 (TROP2) gene expression in thymic carcinoma, thymoma, and normal thymus in The Cancer Genome Atlas data set. TPM, transcripts per million; TROP2, trophoblast cell surface antigen 2.
Figure 2
Figure 2
Immunohistochemical evaluation of TROP2 expression. (A) Representative images of each intensity of TROP2. Intensity 0: absent; Intensity 1: weak to moderate; Intensity 2: strong. (B) Distributions of intensity, proportion, and H-score of TROP2 expression. TROP2, trophoblast cell surface antigen 2.
See this image and copyright information in PMC

References

    1. Scorsetti M., Leo F., Trama A., et al. Thymoma and thymic carcinomas. Crit Rev Oncol Hematol. 2016;99:332–350. - PubMed
    1. National Comprehensive Cancer Network NCCN clinical practice guidelines in oncology: thymomas and thymic carcinomas. Version 1.2024. https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1469 - PubMed
    1. Dum D., Taherpour N., Menz A., et al. Trophoblast cell surface antigen 2 expression in human tumors: a tissue microarray study on 18,563 tumors. Pathobiology. 2022;89:245–258. - PMC - PubMed
    1. Lenart S., Lenart P., Smarda J., Remšík J., Souček K., Beneš P. Trop2: jack of all trades, master of none. Cancers (Basel) 2020;12:3328. - PMC - PubMed
    1. Bardia A., Mayer I.A., Vahdat L.T., et al. Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer. N Engl J Med. 2019;380:741–751. - PubMed

LinkOut - more resources